Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07333547 · ClinicalTrials.gov registry record
Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform
A clinical trial, sponsored by Idoven 1903 S.L..
- Recruiting
- Registry status
- 200,000
- Enrollment target
NCT07333547: Recruiting study, sponsored by Idoven 1903 S.L..
NCT07333547 is a clinical trial that is actively recruiting participants, run by Idoven 1903 S.L.. The registered enrollment target is 200,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07333547 is actively recruiting participants, sponsored by Idoven 1903 S.L..
- RECRUITING
- Registry status
- 200,000 participants
- Enrollment target
Study Summary
The WILLEM Registry is a large-scale, single-group, observational, registry study to collect continuous clinical evidence of Willem in real-world settings. Cardiovascular diseases are a major problem for public health and healthcare systems. Electrocardiograms (ECGs) are simple tests which increase diagnostic performance and early detection of cardiovascular diseases. However, its interpretation is complex, time consuming for cardiology experts, and entails high costs for healthcare systems. Willem allows AI-based automatic interpretation and its performance has been examined in previous clinical trials, but additional clinical evidence is needed for its integration in real-world clinical settings. This study will collect clinical evidence of Willem performance to detect cardiac abnormalities in ECGs from high-risk cardiac patients admitted to cardiovascular units.
Primary Outcome
ECG data will be categorized according to SOC-defined cardiopathies, arrhythmic events, and cardiac diseases. If SOC diagnosis is unavailable or inconsistent, an independent committee of expert cardiologists will review and provide their diagnosis according to a cardiac defined ontology which extends values defined in HL7-aECG data store. Then, the performance of Willem to detect cardiac patterns, arrhythmias, and cardiac disease from ECGs will be assessed. In order to define True Positive, True
Interventions
- DEVICE Willem AI ECG assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200,000 participants |
| Start Date | 2026-02-03 |
| Est. Completion | 2036-01 |
What NCT07333547 shows while recruiting
NCT07333547 is an observational study that tracks outcomes without assigning an intervention. Its 200,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Willem AI ECG assessment is the first listed.
NCT07333547 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07333547 about?
NCT07333547 is a clinical study titled "Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform". The WILLEM Registry is a large-scale, single-group, observational, registry study to collect continuous clinical evidence of Willem in real-world settings. Cardiovascular diseases are a major problem for public health and healthcare systems. Electrocardiograms (ECGs) are simple tests which increase ...
What is the current status of trial NCT07333547?
This trial is currently recruiting. The enrollment target is 200,000 participants. The study started on 2026-02-03. Estimated completion is 2036-01.
What interventions are being tested in trial NCT07333547?
The interventions under investigation include: Willem AI ECG assessment (DEVICE).
Who is sponsoring clinical trial NCT07333547?
This trial is sponsored by Idoven 1903 S.L., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI